Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Opium tincture** is an oral hydroalcoholic pharmaceutical preparation of opium, also called laudanum, standardized in U.S. deodorized products to contain 10 mg/mL anhydrous morphine equivalent. It is a Schedule II opioid preparation used as a nonspecific antidiarrheal; opioid agonism in the gastrointestinal tract increases intestinal smooth-muscle tone and suppresses propulsive contractions, thereby reducing stool frequency and fluid loss. U.S. labeling identifies diarrhea as its indication. Opium tincture has also been studied in Iran as opioid agonist treatment for opioid use disorder and was investigated by Marathon Pharmaceuticals in Phase 3 studies of chronic diarrhea associated with short bowel syndrome. ([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e2a5697a-cc41-4cf1-b3a8-59b0268740d7))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on opium tincture.